Spots Global Cancer Trial Database for germline
Every month we try and update this database with for germline cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | NCT02790944 | Pancreatic Duct... | Multi-gene Next... | 18 Years - 89 Years | Ambry Genetics | |
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | NCT04892693 | Advanced Breast... | Talazoparib Ora... | 19 Years - | Seoul National University Hospital | |
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer | NCT02790944 | Pancreatic Duct... | Multi-gene Next... | 18 Years - 89 Years | Ambry Genetics |